<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-27224" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Pimecrolimus</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Ahn</surname>
            <given-names>David</given-names>
          </name>
          <aff>Walter Reed Medical Center</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Robinson</surname>
            <given-names>Carolyn A.</given-names>
          </name>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>David Ahn declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Carolyn Robinson declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>10</day>
          <month>7</month>
          <year>2023</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-27224.s1" sec-type="Continuing Education Activity">
        <title>Continuing Education Activity</title>
        <p content-type="pubmed-excerpt">Pimecrolimus cream is a prescription non-steroidal medication in the class of topical calcineurin inhibitors (TCIs). It is FDA-approved for the treatment of mild to moderate atopic dermatitis. This article will discuss the mechanism of action, administration, adverse effects, contraindications, monitoring, and theoretical toxicity associated with topical pimecrolimus that is pertinent to members of the healthcare team in the care of patients with atopic dermatitis and other inflammatory skin conditions.</p>
        <p>
<bold>Objectives:</bold>
<list list-type="bullet"><list-item><p>Describe the use of topical steroids and the ancillary role of topical calcineurin inhibitors.</p></list-item><list-item><p>Summarize the use of pimecrolimus in the treatment of atopic dermatitis and other selected inflammatory dermatoses.</p></list-item><list-item><p>Review the mechanism of action of pimecrolimus.</p></list-item><list-item><p>Explain the theoretical risk for toxicity and how appropriate counseling provided by members of the healthcare team can provide reassurance and improve outcomes for patients using topical pimecrolimus.</p></list-item></list>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27224&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27224">Access free multiple choice questions on this topic.</ext-link>
</p>
      </sec>
      <sec id="article-27224.s2" sec-type="Indications">
        <title>Indications</title>
        <p>
<bold>FDA-approved Use</bold>
</p>
        <p>Pimecrolimus cream is an FDA-approved topical calcineurin inhibitor (TCI) to treat mild-moderate atopic dermatitis in patients at least 2 years of age. It is considered a second-line treatment for immunocompetent patients who have failed first-line options such as topical corticosteroids and emollients.</p>
        <p>
<bold>Off-label Use</bold>
</p>
        <p>Off-label use of pimecrolimus cream applies to several inflammatory or otherwise &#x0201c;steroid-responsive&#x0201d; dermatoses, especially for sensitive or thin skin where there may be a higher risk of local side effects related to topical steroids. Such conditions include but are not limited to:</p>
        <list list-type="bullet">
          <list-item>
            <p>Mild to severe atopic dermatitis in patients under 2 years of age<xref ref-type="bibr" rid="article-27224.r1">[1]</xref><xref ref-type="bibr" rid="article-27224.r2">[2]</xref></p>
          </list-item>
          <list-item>
            <p>Eczematous dermatitis of the eyelids,<xref ref-type="bibr" rid="article-27224.r3">[3]</xref> intertriginous (skin fold) areas, or hands<xref ref-type="bibr" rid="article-27224.r4">[4]</xref></p>
          </list-item>
          <list-item>
            <p>Facial and inverse psoriasis<xref ref-type="bibr" rid="article-27224.r5">[5]</xref></p>
          </list-item>
          <list-item>
            <p>Oral and genital lichen planus<xref ref-type="bibr" rid="article-27224.r6">[6]</xref><xref ref-type="bibr" rid="article-27224.r7">[7]</xref></p>
          </list-item>
          <list-item>
            <p>Lichen sclerosis<xref ref-type="bibr" rid="article-27224.r8">[8]</xref></p>
          </list-item>
          <list-item>
            <p>Seborrheic dermatitis<xref ref-type="bibr" rid="article-27224.r9">[9]</xref></p>
          </list-item>
          <list-item>
            <p>Perioral dermatitis<xref ref-type="bibr" rid="article-27224.r10">[10]</xref></p>
          </list-item>
          <list-item>
            <p>Vitiligo<xref ref-type="bibr" rid="article-27224.r11">[11]</xref></p>
          </list-item>
          <list-item>
            <p>Pyoderma gangrenosum<xref ref-type="bibr" rid="article-27224.r12">[12]</xref></p>
          </list-item>
          <list-item>
            <p>Rosacea<xref ref-type="bibr" rid="article-27224.r13">[13]</xref></p>
          </list-item>
          <list-item>
            <p>Cutaneous dermatomyositis<xref ref-type="bibr" rid="article-27224.r14">[14]</xref></p>
          </list-item>
          <list-item>
            <p>Cutaneous lupus erythematosus<xref ref-type="bibr" rid="article-27224.r15">[15]</xref></p>
          </list-item>
          <list-item>
            <p>Cutaneous chronic graft-versus-host disease (GVHD)<xref ref-type="bibr" rid="article-27224.r16">[16]</xref></p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27224.s3" sec-type="Mechanism of Action">
        <title>Mechanism of Action</title>
        <p>Activation of T-lymphocytes starts with the interaction of costimulatory ligands on antigen-presenting cells and T-cell receptors. Intracellular free calcium increases and binds to calmodulin, which activates calcineurin (a protein phosphatase). Calcineurin dephosphorylates the cytoplasmic portion of the transcription factor called nuclear factor of activated T cells (NFAT), which is then transported to the nucleus and contributes to the transcription of several inflammatory cytokines.</p>
        <p>TCIs, by definition, inhibit calcineurin. Pimecrolimus achieves this as it binds to the FK506-binding protein (FKBP) and blocks calcineurin&#x02019;s ability to dephosphorylate NFAT, effectively halting calcineurin-dependent transcription of genes for T-cell activation and production of cytokines such as interleukins 2, 4, and 10 as well as interferon-gamma.</p>
      </sec>
      <sec id="article-27224.s4" sec-type="Administration">
        <title>Administration</title>
        <p>Pimecrolimus is obtained by prescription in a 1% concentration within a cream vehicle; each gram cream contains 10mg of pimecrolimus. Other ingredients&#x000a0;that can be included in the cream base are benzyl alcohol, cetyl alcohol, oleyl alcohol, stearyl alcohol, citric acid, propylene glycol, sodium cetostearyl sulfate, sodium hydroxide, water as well as mono-, di-, and triglycerides. The drug comes in tubes containing 30, 60, or 100 grams.</p>
        <p>Pimecrolimus may be used in combination with steroids,&#x000a0;as&#x000a0;part of an alternating dosing regimen as a steroid-sparing agent, or as monotherapy. The use of topical calcineurin inhibitors 2 to 3 times per week has been shown to proactively reduce flares of atopic dermatitis, and the frequency of use of topical steroids and is more effective than using a bland emollient by itself.<xref ref-type="bibr" rid="article-27224.r1">[1]</xref> A thin layer of pimecrolimus cream is to be applied only to the affected skin twice daily for no longer than 6 weeks continuously. If dermatitis does not respond within that time frame, the patient should seek re-evaluation. Pimecrolimus should not be used under occlusive dressings as its safety has received adequate study under such conditions.</p>
      </sec>
      <sec id="article-27224.s5" sec-type="Adverse Effects">
        <title>Adverse Effects</title>
        <p>The most common side effects of pimecrolimus cream are local sensations of burning, stinging, or pruritus; this may happen, especially when the site of the application is acutely inflamed. Generally, these side effects will improve with repetitive use or mitigated by using topical steroids before the initiation of pimecrolimus.</p>
        <p>Several other side effects have been reported with the use of topical pimecrolimus, although they are relatively uncommon or have not been proven to be a direct result of treatment. Atopic patients, in particular, are at a higher risk than the general population of certain bacterial and viral skin infections such as <italic toggle="yes">Staphylococcus aureus</italic> colonization leading to impetigo or more widespread distribution of herpetic lesions called eczema herpeticum. The current prescribing instructions state to avoid use on active infections, and patients should have counseling on the possibility of skin infections due to limited long-term safety data.</p>
        <p>Other possible adverse effects include application site reaction (i.e., erythema or skin discoloration), headache, fever, flu-like symptoms, nasopharyngitis or nasal congestion, sinusitis, epistaxis, upper respiratory tract infection, sore throat, tonsillitis, cough, bronchitis, dyspnea, pneumonia, asthma or asthma exacerbation, folliculitis, acne, urticaria, constipation, diarrhea, gastroenteritis, nausea, vomiting, abdominal pain, toothache, dysmenorrhea, hypersensitivity, arthralgia, conjunctivitis, eye infection, ear infection, anaphylaxis, angioedema, lymphadenopathy, and malignancy (basal cell carcinoma, squamous cell carcinoma, malignant melanoma, and lymphoma).<xref ref-type="bibr" rid="article-27224.r17">[17]</xref></p>
      </sec>
      <sec id="article-27224.s6" sec-type="Contraindications">
        <title>Contraindications</title>
        <p>
<bold>Absolute Contraindication</bold>
<xref ref-type="bibr" rid="article-27224.r18">[18]</xref>
</p>
        <list list-type="bullet">
          <list-item>
            <p>History of hypersensitivity to pimecrolimus or any other ingredients included in the cream formulation</p>
          </list-item>
        </list>
        <p>
<bold>When Pimecrolimus Cream Should be Avoided</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Patients who are immunocompromised or are taking systemic immunosuppressive medications</p>
          </list-item>
          <list-item>
            <p>Areas of skin with active pre-malignant or malignant lesions (such as cutaneous T-cell lymphoma (CTCL)) or skin infections (bacterial or viral)</p>
          </list-item>
          <list-item>
            <p>Patients who have severely impaired skin barrier function that may be at higher risk for increased systemic absorption (i.e., Netherton syndrome)</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-27224.s7" sec-type="Monitoring">
        <title>Monitoring</title>
        <p>Calcineurin inhibitors applied topically have been shown to have negligible rates of systemic absorption. There is no recommendation for routine blood monitoring of patients using topical pimecrolimus.</p>
      </sec>
      <sec id="article-27224.s8" sec-type="Toxicity">
        <title>Toxicity</title>
        <p>Topical pimecrolimus is rated category C as there have been no adequate studies in pregnant women.</p>
        <p>TCIs such as pimecrolimus have a black-box warning from theoretical risks based on high dose systemic calcineurin inhibitor use in post-transplant patients and animal studies.<xref ref-type="bibr" rid="article-27224.r19">[19]</xref> There is an increased risk of infections, lymphoma, and skin malignancies in those study populations that correlates positively with the dosage and duration of systemic immunosuppression. Although there has been no definite establishment of a causal relationship, skin malignancies and lymphomas have rarely been reported in patients using topical pimecrolimus. Patients or parents should be made aware of the black-box warning but reassured that the risk of malignancy is low when adhering to the proper use of topical calcineurin inhibitors.</p>
        <p>Some formulations of topical pimecrolimus contain benzyl alcohol and propylene glycol as inactive ingredients, which have been reported to cause serious adverse effects in neonates.<xref ref-type="bibr" rid="article-27224.r20">[20]</xref> Benzyl alcohol toxicity has been known to cause &#x0201c;gasping syndrome&#x0201d; in neonate<italic toggle="yes">s </italic>when administered intravenously, and large amounts of propylene glycol administered orally, intravenously, or topically may also result in neonate fatality.<xref ref-type="bibr" rid="article-27224.r21">[21]</xref> No such reports stem directly from the use of benzyl alcohol or propylene glycol in topical pimecrolimus; in fact, data from clinical trials support the safe and effective use of pimecrolimus off-label in children less than 2 years of age and infants.<xref ref-type="bibr" rid="article-27224.r2">[2]</xref></p>
      </sec>
      <sec id="article-27224.s9" sec-type="Enhancing Healthcare Team Outcomes ">
        <title>Enhancing Healthcare Team Outcomes </title>
        <p>Inflammatory dermatoses are often treated by primary care providers, nurse practitioners, dermatologists, and rheumatologists. Topical steroids have long been considered first-line treatment for inflammatory dermatoses but may cause local side effects including skin atrophy, telangiectasias, striae, acneiform eruptions, and rarely cataracts or glaucoma. Pimecrolimus is a non-steroidal agent belonging to the class of topical calcineurin inhibitors (TCIs) initially approved in the United States in 2001. Out of numerous ascomycin derivatives screened, researchers selected pimecrolimus for further development based on favorable anti-inflammatory properties, skin-selective properties, and overall safety profile. Although topical steroids are still regarded as first-line treatment for dermatitis, in some clinical scenarios, TCIs may even be preferred to topical steroids, such as when the skin condition is recalcitrant to steroids or located on sensitive skin or if the patient has experienced local side effects from topical steroids.</p>
        <p>Therapy with pimecrolimus requires an interprofessional team approach. Clinicians (MDs, DOs, NPs, PAs), including specialists, will initiate treatment but should use pharmacist resources to verify dosing and indications, as well as potential drug-drug interactions. The pharmacist can also consult with nursing, so they can be alert for possible adverse effects, which with pimecrolimus can be severe. The nurse is also well-positioned to evaluate compliance and report any adverse events or the success or failure of therapy to the rest of the team. This type of interprofessional collaboration will optimize patient outcomes and minimize adverse reactions. [Level 5]</p>
        <p>In 2014, a workgroup consisting of experts in atopic dermatitis put forth an update on evidence-based treatment guidelines. The results explicitly addressing the use of topical calcineurin inhibitors are summarized below<xref ref-type="bibr" rid="article-27224.r1">[1]</xref>:</p>
        <p>
<bold>Level of Evidence: I Strength of Recommendation: A</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>In treating atopic dermatitis, TCIs such as pimecrolimus are more efficacious than monotherapy with an emollient. When used as regularly (2 to 3 times weekly), atopic flares decrease, and patients require topical steroids less frequently.</p>
          </list-item>
          <list-item>
            <p>TCIs, such as pimecrolimus, can be recommended for use as steroid-sparing options on actively inflamed areas of atopic dermatitis.</p>
          </list-item>
          <list-item>
            <p>Off-label use of pimecrolimus cream can be recommended in atopic dermatitis patients less than 2 years of age.</p>
          </list-item>
          <list-item>
            <p>There currently is no recommendation for routine blood monitoring in patients using TCIs.</p>
          </list-item>
        </list>
        <p>
<bold>Level of Evidence: II Strength of Recommendation: B</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Localized skin burning, stinging, or pruritus is the most common adverse effects associated with the use of TCIs, particularly when applied to areas of acute dermatitis. Patients should receive counsel on these possible side effects and how to limit them. These symptoms may decrease over time with repetitive use or with pretreatment with topical steroids.</p>
          </list-item>
          <list-item>
            <p>TCIs may be used simultaneously with topical steroids.</p>
          </list-item>
        </list>
        <p>
<bold>Level of Evidence: III Strength of Recommendation: C</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>As TCIs are a relatively new class of medication, there is no long-term safety data. Data regarding viral skin infections with the use of topical calcineurin inhibitors continuously or intermittently up to 5 years demonstrates no increased prevalence; however, patients should still understand the theoretical risk.</p>
          </list-item>
          <list-item>
            <p>Prescribers should be aware of and counsel patients regarding the black-box warning for topical calcineurin inhibitors.</p>
          </list-item>
        </list>
        <p>With increased familiarity with current recommendations, members of the healthcare team can ensure more favorable outcomes in patients with atopic dermatitis and other inflammatory dermatoses receiving treatment with topical pimecrolimus.</p>
      </sec>
      <sec id="article-27224.s10">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=27224&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=27224">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/27224/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=27224">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-27224.s11">
        <title>References</title>
        <ref id="article-27224.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Eichenfield</surname>
                <given-names>LF</given-names>
              </name>
              <name>
                <surname>Tom</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Berger</surname>
                <given-names>TG</given-names>
              </name>
              <name>
                <surname>Krol</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Paller</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Schwarzenberger</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Bergman</surname>
                <given-names>JN</given-names>
              </name>
              <name>
                <surname>Chamlin</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Cohen</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Cooper</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>Cordoro</surname>
                <given-names>KM</given-names>
              </name>
              <name>
                <surname>Davis</surname>
                <given-names>DM</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>SR</given-names>
              </name>
              <name>
                <surname>Hanifin</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Margolis</surname>
                <given-names>DJ</given-names>
              </name>
              <name>
                <surname>Silverman</surname>
                <given-names>RA</given-names>
              </name>
              <name>
                <surname>Simpson</surname>
                <given-names>EL</given-names>
              </name>
              <name>
                <surname>Williams</surname>
                <given-names>HC</given-names>
              </name>
              <name>
                <surname>Elmets</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Block</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Harrod</surname>
                <given-names>CG</given-names>
              </name>
              <name>
                <surname>Smith Begolka</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Sidbury</surname>
                <given-names>R</given-names>
              </name>
            </person-group>
            <article-title>Guidelines of care for the management of atopic dermatitis: section 2. Management and treatment of atopic dermatitis with topical therapies.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2014</year>
            <month>Jul</month>
            <volume>71</volume>
            <issue>1</issue>
            <fpage>116</fpage>
            <page-range>116-32</page-range>
            <pub-id pub-id-type="pmid">24813302</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>El-Batawy</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Bosseila</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Mashaly</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Hafez</surname>
                <given-names>VS</given-names>
              </name>
            </person-group>
            <article-title>Topical calcineurin inhibitors in atopic dermatitis: a systematic review and meta-analysis.</article-title>
            <source>J Dermatol Sci</source>
            <year>2009</year>
            <month>May</month>
            <volume>54</volume>
            <issue>2</issue>
            <fpage>76</fpage>
            <page-range>76-87</page-range>
            <pub-id pub-id-type="pmid">19303745</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Murrell</surname>
                <given-names>DF</given-names>
              </name>
              <name>
                <surname>Calvieri</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Ortonne</surname>
                <given-names>JP</given-names>
              </name>
              <name>
                <surname>Ho</surname>
                <given-names>VC</given-names>
              </name>
              <name>
                <surname>Weise-Riccardi</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barbier</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Paul</surname>
                <given-names>CF</given-names>
              </name>
            </person-group>
            <article-title>A randomized controlled trial of pimecrolimus cream 1% in adolescents and adults with head and neck atopic dermatitis and intolerant of, or dependent on, topical corticosteroids.</article-title>
            <source>Br J Dermatol</source>
            <year>2007</year>
            <month>Nov</month>
            <volume>157</volume>
            <issue>5</issue>
            <fpage>954</fpage>
            <page-range>954-9</page-range>
            <pub-id pub-id-type="pmid">17935515</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>GR</given-names>
              </name>
              <name>
                <surname>Maarouf</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hendricks</surname>
                <given-names>AK</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>DE</given-names>
              </name>
              <name>
                <surname>Shi</surname>
                <given-names>VY</given-names>
              </name>
            </person-group>
            <article-title>Current and emerging therapies for hand eczema.</article-title>
            <source>Dermatol Ther</source>
            <year>2019</year>
            <month>May</month>
            <volume>32</volume>
            <issue>3</issue>
            <fpage>e12840</fpage>
            <pub-id pub-id-type="pmid">30693618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Dattola</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Silvestri</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Bennardo</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Del Duca</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Longo</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bianchi</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Nistic&#x000f2;</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Update of calcineurin inhibitors to treat inverse psoriasis: A systematic review.</article-title>
            <source>Dermatol Ther</source>
            <year>2018</year>
            <month>Nov</month>
            <volume>31</volume>
            <issue>6</issue>
            <fpage>e12728</fpage>
            <pub-id pub-id-type="pmid">30295379</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Sun</surname>
                <given-names>SL</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Zhong</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>JK</given-names>
              </name>
              <name>
                <surname>Jin</surname>
                <given-names>X</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Yin</surname>
                <given-names>FY</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>TN</given-names>
              </name>
              <name>
                <surname>Chen</surname>
                <given-names>QM</given-names>
              </name>
              <name>
                <surname>Zeng</surname>
                <given-names>X</given-names>
              </name>
            </person-group>
            <article-title>Topical calcineurin inhibitors in the treatment of oral lichen planus: a systematic review and meta-analysis.</article-title>
            <source>Br J Dermatol</source>
            <year>2019</year>
            <month>Dec</month>
            <volume>181</volume>
            <issue>6</issue>
            <fpage>1166</fpage>
            <page-range>1166-1176</page-range>
            <pub-id pub-id-type="pmid">30903622</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lonsdale-Eccles</surname>
                <given-names>AA</given-names>
              </name>
              <name>
                <surname>Velangi</surname>
                <given-names>S</given-names>
              </name>
            </person-group>
            <article-title>Topical pimecrolimus in the treatment of genital lichen planus: a prospective case series.</article-title>
            <source>Br J Dermatol</source>
            <year>2005</year>
            <month>Aug</month>
            <volume>153</volume>
            <issue>2</issue>
            <fpage>390</fpage>
            <page-range>390-4</page-range>
            <pub-id pub-id-type="pmid">16086755</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Goldstein</surname>
                <given-names>AT</given-names>
              </name>
              <name>
                <surname>Creasey</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Pfau</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Phillips</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Burrows</surname>
                <given-names>LJ</given-names>
              </name>
            </person-group>
            <article-title>A double-blind, randomized controlled trial of clobetasol versus pimecrolimus in patients with vulvar lichen sclerosus.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2011</year>
            <month>Jun</month>
            <volume>64</volume>
            <issue>6</issue>
            <fpage>e99</fpage>
            <page-range>e99-104</page-range>
            <pub-id pub-id-type="pmid">21353334</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhao</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Sun</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Wu</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Le</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Liu</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Xiang</surname>
                <given-names>L</given-names>
              </name>
            </person-group>
            <article-title>Comparison of different regimens of pimecrolimus 1% cream in the treatment of facial seborrheic dermatitis.</article-title>
            <source>J Cosmet Dermatol</source>
            <year>2018</year>
            <month>Feb</month>
            <volume>17</volume>
            <issue>1</issue>
            <fpage>90</fpage>
            <page-range>90-94</page-range>
            <pub-id pub-id-type="pmid">28589618</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schwarz</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kreiselmaier</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Bieber</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Thaci</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Simon</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Meurer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Werfel</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Zuberbier</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Luger</surname>
                <given-names>TA</given-names>
              </name>
              <name>
                <surname>Wollenberg</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Br&#x000e4;utigam</surname>
                <given-names>M</given-names>
              </name>
            </person-group>
            <article-title>A randomized, double-blind, vehicle-controlled study of 1% pimecrolimus cream in adult patients with perioral dermatitis.</article-title>
            <source>J Am Acad Dermatol</source>
            <year>2008</year>
            <month>Jul</month>
            <volume>59</volume>
            <issue>1</issue>
            <fpage>34</fpage>
            <page-range>34-40</page-range>
            <pub-id pub-id-type="pmid">18462835</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lee</surname>
                <given-names>JH</given-names>
              </name>
              <name>
                <surname>Kwon</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Jung</surname>
                <given-names>HM</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>GM</given-names>
              </name>
              <name>
                <surname>Yim</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Bae</surname>
                <given-names>JM</given-names>
              </name>
            </person-group>
            <article-title>Treatment Outcomes of Topical Calcineurin Inhibitor Therapy for Patients With Vitiligo: A Systematic Review and Meta-analysis.</article-title>
            <source>JAMA Dermatol</source>
            <year>2019</year>
            <month>Aug</month>
            <day>01</day>
            <volume>155</volume>
            <issue>8</issue>
            <fpage>929</fpage>
            <page-range>929-938</page-range>
            <pub-id pub-id-type="pmid">31141108</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Abdul-Fattah</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Al-Muriesh</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>CZ</given-names>
              </name>
            </person-group>
            <article-title>Efficacy of topical calcineurin inhibitors in pyoderma gangrenosum.</article-title>
            <source>Dermatol Ther</source>
            <year>2018</year>
            <month>Sep</month>
            <volume>31</volume>
            <issue>5</issue>
            <fpage>e12697</fpage>
            <pub-id pub-id-type="pmid">30252999</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r13">
          <label>13</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>MB</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>GW</given-names>
              </name>
              <name>
                <surname>Park</surname>
                <given-names>HJ</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>HS</given-names>
              </name>
              <name>
                <surname>Chin</surname>
                <given-names>HW</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Kim</surname>
                <given-names>BS</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>HC</given-names>
              </name>
            </person-group>
            <article-title>Pimecrolimus 1% cream for the treatment of rosacea.</article-title>
            <source>J Dermatol</source>
            <year>2011</year>
            <month>Dec</month>
            <volume>38</volume>
            <issue>12</issue>
            <fpage>1135</fpage>
            <page-range>1135-9</page-range>
            <pub-id pub-id-type="pmid">21954922</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r14">
          <label>14</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Kim</surname>
                <given-names>JE</given-names>
              </name>
              <name>
                <surname>Jeong</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Lee</surname>
                <given-names>HE</given-names>
              </name>
              <name>
                <surname>Ko</surname>
                <given-names>JY</given-names>
              </name>
              <name>
                <surname>Ro</surname>
                <given-names>YS</given-names>
              </name>
            </person-group>
            <article-title>Successful treatment of cutaneous lesions of dermatomyositis with topical pimecrolimus.</article-title>
            <source>Ann Dermatol</source>
            <year>2011</year>
            <month>Aug</month>
            <volume>23</volume>
            <issue>3</issue>
            <fpage>348</fpage>
            <page-range>348-51</page-range>
            <pub-id pub-id-type="pmid">21909206</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r15">
          <label>15</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Wollina</surname>
                <given-names>U</given-names>
              </name>
              <name>
                <surname>Hansel</surname>
                <given-names>G</given-names>
              </name>
            </person-group>
            <article-title>The use of topical calcineurin inhibitors in lupus erythematosus: an overview.</article-title>
            <source>J Eur Acad Dermatol Venereol</source>
            <year>2008</year>
            <month>Jan</month>
            <volume>22</volume>
            <issue>1</issue>
            <fpage>1</fpage>
            <page-range>1-6</page-range>
            <pub-id pub-id-type="pmid">18005117</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r16">
          <label>16</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Schmook</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Kraft</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Benninghoff</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Nindl</surname>
                <given-names>I</given-names>
              </name>
              <name>
                <surname>Roewert</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Ulrich</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Stockfleth</surname>
                <given-names>E</given-names>
              </name>
            </person-group>
            <article-title>Treatment of cutaneous chronic graft-versus-host disease with topical pimecrolimus.</article-title>
            <source>Bone Marrow Transplant</source>
            <year>2005</year>
            <month>Jul</month>
            <volume>36</volume>
            <issue>1</issue>
            <fpage>87</fpage>
            <page-range>87-8</page-range>
            <pub-id pub-id-type="pmid">15895116</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r17">
          <label>17</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hanna</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Zip</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Shear</surname>
                <given-names>NH</given-names>
              </name>
            </person-group>
            <article-title>What Is the Risk of Harm Associated With Topical Calcineurin Inhibitors?</article-title>
            <source>J Cutan Med Surg</source>
            <year>2019</year>
            <season>Sep/Oct</season>
            <volume>23</volume>
            <issue>4_suppl</issue>
            <fpage>19S</fpage>
            <page-range>19S-26S</page-range>
            <pub-id pub-id-type="pmid">31476938</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r18">
          <label>18</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Fleischer</surname>
                <given-names>AB</given-names>
              </name>
            </person-group>
            <article-title>Black box warning for topical calcineurin inhibitors and the death of common sense.</article-title>
            <source>Dermatol Online J</source>
            <year>2006</year>
            <month>Oct</month>
            <day>31</day>
            <volume>12</volume>
            <issue>6</issue>
            <fpage>2</fpage>
            <pub-id pub-id-type="pmid">17083882</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r19">
          <label>19</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Tennis</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Gelfand</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Rothman</surname>
                <given-names>KJ</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of cancer risk related to atopic dermatitis and use of topical calcineurin inhibitors.</article-title>
            <source>Br J Dermatol</source>
            <year>2011</year>
            <month>Sep</month>
            <volume>165</volume>
            <issue>3</issue>
            <fpage>465</fpage>
            <page-range>465-73</page-range>
            <pub-id pub-id-type="pmid">21466537</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r20">
          <label>20</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Shehab</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>CL</given-names>
              </name>
              <name>
                <surname>Streetman</surname>
                <given-names>DD</given-names>
              </name>
              <name>
                <surname>Donn</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Exposure to the pharmaceutical excipients benzyl alcohol and propylene glycol among critically ill neonates.</article-title>
            <source>Pediatr Crit Care Med</source>
            <year>2009</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>2</issue>
            <fpage>256</fpage>
            <page-range>256-9</page-range>
            <pub-id pub-id-type="pmid">19188870</pub-id>
          </element-citation>
        </ref>
        <ref id="article-27224.r21">
          <label>21</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Gershanik</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Boecler</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ensley</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>McCloskey</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>George</surname>
                <given-names>W</given-names>
              </name>
            </person-group>
            <article-title>The gasping syndrome and benzyl alcohol poisoning.</article-title>
            <source>N Engl J Med</source>
            <year>1982</year>
            <month>Nov</month>
            <day>25</day>
            <volume>307</volume>
            <issue>22</issue>
            <fpage>1384</fpage>
            <page-range>1384-8</page-range>
            <pub-id pub-id-type="pmid">7133084</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
